IRF-8/miR-451a regulates M-MDSC differentiation via the AMPK/mTOR signal pathway during lupus development

Guoping Shi1,4, Dan Li1,4, Dongya Zhang1,4, Yujun Xu1, Yuchen Pan1, Li Lu1, Jingman Li1, Xiaoyu Xia1, Huan Dou1,2,3✉ and Yayi Hou1,2,3✉

© The Author(s) 2021

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease. Myeloid-derived suppressor cells (MDSCs) have been found to be involved in the regulation of SLE development. However, little is known about the association between MDSC subsets and the factors that draw MDSCs into abnormal expansion. This study found that the percentage of M-MDSCs increased in mice with pristane-induced lupus. Toll-like receptor (TLR)7 signal activation and high interferon-α (IFN-α) level promoted M-MDSC differentiation in vitro. Moreover, both AMP-activated protein kinase (AMPK) agonist metformin and two mammalian targets of rapamycin (mTOR) inhibitors (INK128 and rapamycin) inhibited the percentage of M-MDSCs in lupus mice as well as in the TLR7- and IFN-α-induced bone marrow (BM) differentiation into MDSCs in vitro. In terms of mechanism, whole-genome transcriptome profiling was performed by RNA sequencing, revealing that the expression of the transcription factor IRF-8 was higher in M-MDSCs isolated from pristane-induced lupus mice, compared with control mice. IRF-8 was identified to be crucial for TLR7- and IFN-α-induced BM differentiation into MDSCs in vitro. Furthermore, interferon (IFN) regulatory factor8 (IRF-8) was targeted by miR-451a in M-MDSC differentiation. Of note, metformin-modified M-MDSCs could relieve lupus symptoms in pristane-induced lupus mice. The findings revealed a novel mechanism linking IRF-8/miR-451a to M-MDSC differentiation via the AMPK/mTOR signal pathway during lupus development. This study might provide an important reference for SLE therapy by targeting M-MDSCs.

Cell Death Discovery (2021) 7:179; https://doi.org/10.1038/s41420-021-00568-z

INTRODUCTION

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease characterized by ubiquitous autoantibody production, immune complex deposition, multiple-organ dysfunction, and aberrant tissue inflammation [1]. Several environmental, hormonal, and genetic factors play important roles during the development of SLE [2, 3]. Pristane (tetramethylpentadecane)-induced lupus is a murine model of SLE, facilitating research into the role of environmental factors in autoimmunity [4]. This murine lupus model is quite suitable for examining the links between dysregulated IFN-α production and the pathogenesis of human SLE. An increasing body of evidence suggests that early immune cells are highly important in the development of immune-mediated inflammation in SLE [5, 6]. Lupus flares are associated with a relative increase in the frequency of macrophages [7]. The frequency of inflammatory monocytes is also elevated in patients with SLE [8]. The number of plasmacytoid DCs (pDCs) decreases in the blood and accumulates in lesional skin or kidneys [9, 10]. Till 2010, the abnormalities of myeloid-derived suppressor cells (MDSCs) were found to be involved in the regulation of the innate immune response in autoimmune disorders [11].

MDSCs are a heterogeneous population of myeloid lineage cells derived from immature myeloid progenitors, which expand during chronic and acute inflammatory conditions [12, 13]. Murine MDSCs are characterized as CD11b+Gr1+ cells and can be typically divided into two subpopulations: G-MDSCs (CD11b+Ly6CloLy6G−) and M-MDSCs (CD11b+Ly6C+Ly6G+) [12, 13]. Some findings on MDSCs in SLE are controversial [14-17]. A previous study showed that the frequencies of MDSCs were remarkably elevated in peripheral blood samples from patients with SLE, MRL/lpr mice, IMQ-lupus-prone mice, and mice with pristane-induced lupus [18-20]. In MRL/lpr lupus-prone mice, the splenic G-MDSCs expanded and positively correlated with disease severity [20]. The adoptive transfer of lupus MDSCs led to severe proteinuria and autoimmunity, impairing regulatory T(Treg) cells differentiation and promoting Th17 cell polarization [20]. Moreover, myeloid-derived CD11b+Gr1+ cells were confirmed to increase prior to abnormal changes in T and B cells during pristane-induced lupus development, and the mTOR pathway was critical for MDSCs in lupus development [21]. In mice with Toll-like receptor-7 (TLR7) agonist imiquimod-induced lupus, a significant expansion of MDSCs induced podocyte injury through increasing ROS in lupus nephritis (LN) [22]. These observations suggested that total MDSCs and their subsets played crucial roles in SLE development. Indeed, with heterogeneity among MDSCs and differential effects among subpopulations receiving much attention, understanding the...
abnormal differentiation mechanism of MDSC subtypes is crucial to reveal the role of MDSCs in SLE development.

Under normal physiological conditions, MDSCs are differentiated in bone marrow (BM) from hematopoietic progenitor cells and rapidly develop into neutrophils, monocytes, dendritic cells, and mature macrophages. Conversely, under pathological conditions, immature myeloid cells are expanded and converted into immunosuppressive MDSCs [23]. This implies that the differentiation of MDSCs is a complex and gradual phenomenon governed by multiple factors. IRF-8, a myeloid lineage-specific transcription factor, drives the differentiation of hematopoietic stem cells into granulocytes and macrophages via a distinct program [24–26]. Studies have confirmed that IRF-8 can regulate the differentiation of MDSCs in a variety of diseases, including breast cancer, colitis-associated colon cancer, and intestinal nematode infection [27–29]. In the pathogenesis of SLE, clinical large-scale data analysis showed that IRF-8 was closely related to the increased risk of SLE [30–34]. However, whether IRF-8 concentrated on the differentiation of MDSC subtypes in SLE development needs to be clarified.

A previous study showed that TLR7/IFN-α-mTOR signaling was significantly activated in total MDSCs in mice with early-aged lupus, suggesting that the abnormal differentiation of MDSCs might provide an important insight into the early diagnosis and treatment of SLE [21]. Moreover, this study provided evidence that INK128, a second-generation mTOR inhibitor, attenuated SLE by regulating total MDSCs [21]. Recently, the agonist for AMPK (upstream molecule of mTOR signal), metformin, was reported to relieve lupus symptoms by regulating abnormal T and B cells [35, 36]. Thus, it was hypothesized that metformin might improve lupus symptoms by regulating the differentiation of MDSCs during SLE development.

For a better understanding of the role of MDSC subtypes in SLE, the pristane-induced lupus murine model was used in the present study, characterized by high serum IFN-α levels and dysregulation of cellular immunity [21, 37, 38]. The changes in MDSC subtypes in mice under pristane induction were exhaustively detected. In vitro and in vivo experimental analyses were applied to determine whether AMPK/mTOR signaling was involved in the TLR7/IFN-α-prompted differentiation of MD-MDSCs. In terms of mechanism, whole-genome transcriptome profiling was performed by RNA sequencing, trying to compare the differences between MDSCs in the normal physiological state and in SLE pathogenesis, as well as in the factors regulating the differentiation of MDSC subtypes. In all, the percentage of M-MDSCs significantly increased in mice with pristane-induced lupus, and AMPK/mTOR signaling was included in the differentiation of M-MDSCs. IRF-8 is crucial for TLR7/IFN-α-induced BM cell differentiation into M-MDSCs in vitro, being targeted by miR-451a. These findings indicated that metformin could regulate the differentiation of M-MDSCs precisely via IRF-8/miR-451a and have a potential therapeutic effect on lupus development.

RESULTS
Both TLR7 signaling activation and IFN-α promoted the differentiation of M-MDSCs

The percentage of total MDSCs (CD11b+Gr1+ cells) was found to be elevated in the early stage of lupus progression [21]. To further study the role of MDSC subtypes (M-MDSCs and G-MDSCs), the changes in MDSC subtypes were detected in a pristane-induced lupus mouse model. As shown in Fig. 1A, M-MDSCs increased in BM (Fig. 1A), spleen (Fig. 1B), kidney cells (Fig. 1C), and lung (Fig. 1D) in the lupus model mice compared with the control mice. On assaying the percentage of M-MDSCs in CD11b+Gr1+ myeloid cells, we found that the percentage of M-MDSCs was elevated in BM (Fig. S1C), kidney cells (Fig. S1F), spleen (Fig. S1H), and lung (Fig. S1L). We also found that the percentage of G-MDSCs in total cells was elevated in BM (Fig. S1A), kidney cells (Fig. S1D), spleen (Fig. S1G), and lung (Fig. S1J), while the percentage of G-MDSCs reduced in CD11b+Gr1+ myeloid cells in BM (Fig. S1B), kidney cells (Fig. S1E), spleen (Fig. S1H), and lung (Fig. S1K).

Next, the factors in the lupus microenvironment that could affect the differentiation of M-MDSCs were identified. Our previous study found that the activation of TLR7 signal and high IFN-α level was related to the differentiation of total CD11b+Gr1+ MDSCs [21]. However, the effect of TLR7 signal and IFN-α on M-MDSC is unclear [21]. To explore which MDSC subtypes were mainly affected in BM differentiation into MDSCs, BM cells were cultured in a medium supplemented with 40 ng/mL interleukin-6 (IL-6) and 40 ng/mL granulocyte-macrophage colony-stimulating factor (GM-CSF) for 4 days. When stimulated with TLR7 agonist R848 in the culture, M-MDSCs increased (Fig. 1E–H) while G-MDSCs decreased (Fig. S1M, N) in a time- and dose-dependent manner. In addition, when stimulated with IFN-α, M-MDSCs (Fig. 1I–L) and G-MDSCs (Fig. S1O, P) also had similar effects. These results suggested that TLR7 and IFN-α in the lupus microenvironment might promote the differentiation of M-MDSCs in pristane-induced lupus mice.

Furthermore, to assay the variations in MDSC subtypes, M-MDSCs and G-MDSCs were respectively purified from spleens in mice with lupus and control mice using a MDSC isolation kit. Then, whole-genome transcriptome profiling was performed by RNA sequencing, and an EBseq algorithm was applied to filter the differentially expressed genes. First, differential mRNAs were found through mRNA-seq in M-MDSCs and G-MDSCs. Subsequently, the function of differential mRNAs was explored by pathway analysis, revealing that DNA replication pathway, Histidine metabolism pathway, Vitamin B6 metabolism pathway, Sulfur relay system pathway, and the SLE signal pathway were significantly different pathways (TOP 25) in M-MDSCs (Fig. S2A, B). SLE signal pathway, Alcoholism pathway, Viral carcinogenesis pathway, Transcriptional misregulation in cancer pathway, and Cell cycle pathway were significant differential pathways (TOP 25) in G-MDSCs (Fig. S2A, B). We found that SLE signal pathway was a significantly different signaling pathway in both M-MDSC and G-MDSCs. Histone- and complement-related molecules in the SLE pathway changed significantly in M-MDSCs (Fig. S2C). Next, we analyzed the relationship between the most significant differential genes and TLR7 and IFN-α signaling pathways in M-MDSCs (Fig. S3A) and G-MDSCs (Fig. S3B). We found that TLR7/IFN-α signaling pathway plays a key role in regulating differential genes. This result suggested that the activation of TLR7/IFN-α signaling pathway in both M-MDSCs and G-MDSCs might play an important role in SLE development.

AMPK regulated the differentiation of M-MDSCs in mice with pristane-induced lupus

A previous study found that mTOR inhibition could attenuate lupus symptoms by regulating the differentiation and functions of total CD11b+Gr1+ MDSCs. AMPK is an important upstream regulator of the mTOR signal. Metformin, as AMPK agonist, could inhibit mTOR by activating AMPK. Metformin relieved lupus symptoms by regulating abnormal T and B cells in a genetic background lupus mouse model [35, 36]. However, the therapeutic effect of metformin on environment factor pristane-induced SLE and the exact mechanism of action of metformin on the differentiation of M-MDSCs were unclear.

First, to determine the effect of metformin on environment factor-induced SLE, pristane-induced lupus mice were treated with metformin for 2 months. As shown in Fig. 2A, kidneys from metformin-treated mice with lupus showed a better effect on glomerulonephritis and infiltration of lymphocytes compared with vehicle-treated mice with lupus. Metformin decreased proteinuria (Fig. 2B) and serum immunoglobulin G (IgG) and anti-dsDNA IgG levels (Fig. 2C), which significantly increased in vehicle-treated mice with lupus. Metformin also gradually attenuated lung
inflammation, which was severe in mice with pristane-induced lupus (Fig. 2D). In addition, metformin attenuated inflammatory infiltration and bone erosion in the tarsal joints of mice with lupus (Fig. 2E). These results together indicated that metformin had a therapeutic effect on environment factor pristane-induced SLE. The level of each MDSC subtype was quantified in the different tissues analyzed from metformin-treated SLE mice. We found that metformin significantly reduced the proportion of MDSCs subtypes, especially M-MDSCs (Fig. S4).

Next, to further explore whether the therapeutic effect of metformin on lupus was exerted by regulating M-MDSCs, four groups were set: control group, MDSC deletion group, lupus mice-derived M-MDSC adoptive transfer group, and metformin-treated M-MDSC adoptive transfer group. The effects of each group on lupus symptoms were tested 1 month later. The results showed that MDSC deletion could improve lupus symptoms, while the adoptive transfer of M-MDSCs derived from lupus mice could accelerate disease progression. Moreover, when metformin-treated M-MDSCs were infused into mice with lupus, lupus symptoms were in remission compared with the lupus mice-derived M-MDSC adoptive transfer group (Fig. 2F–K). Taken together, AMPK activation...
AMPK signal activation could attenuate lupus symptoms by regulating M-MDSCs differentiation in pristane-induced lupus mice.

BALB/c mice (10 weeks, n = 6–8/group) were given a single intraperitoneal injection of 0.5 ml pristane or PBS and monitored for 7 months. Metformin-treated lupus mice for 2 months after 5 months pristane injection. A Kidney sections from each group showed histologic differences. B Proteinuria in each group was determined using Mouse Albumin ELISA Quantitation Set. C Serum levels of total IgG and IgG against dsDNA were determined by ELISA. D Lung sections from each group showed histologic differences. E Representative photographs of paws from each group. F–K Gr1mAb, M-MDSCs or Metformin-treated lupus M-MDSCs treated mice for 1 month. F Kidney sections from each group showed histologic differences. G Serum levels of total IgG and IgG against dsDNA were determined by ELISA Quantitation Set. H Proteinuria in each group was determined using mouse albumin. I, K Lung sections from each group showed histologic differences. J, K Representative histological sections of tarsal hind paw joints. Data represent the mean ± SEM. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
could attenuate lupus symptoms by regulating the differentiation of M-MDSCs in mice with pristane-induced lupus.

M-MDSCs decreased by modulating the AMPK/mTOR signal pathway in vivo

To confirm the role of the AMPK/mTOR pathway in M-MDSC expansion, BALB/c mice were injected with 0.5 mL of pristane. After 5 months, mice with lupus were treated with vehicle, AMPK agonist metformin, and mTOR inhibitors INK128 and rapamycin for another 2 months. As shown in Fig. 3A–E, mice with lupus treated with metformin, INK128, and rapamycin had a decreased percentage of total MDSCs in lungs (Fig. 3A), bone marrow (BM) (B), PECs (C), spleen (D). The statistical graphs are shown. The percentage of M-MDSCs in lungs (E), bone marrow (BM) (F), PECs (G), spleen (H). The statistical graphs are shown. Data represent the mean ± SEM. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.

Furthermore, inhibiting the mTOR signal could reverse the abnormal expression of surface molecules (GO:001620) identified by Gene Ontology (GO) analysis among the differentially expressed genes and the SLE signal-related molecules (PATH ID:05322) identified by pathway analysis on M-MDSCs and G-MDSCs in mice with pristane-induced lupus (Fig. S5). Among the surface molecules, the expression of CD55, CD86, CD93, and CCR6 were decreased in G-MDSCs from pristane-induce lupus mice, and INK128 could increase the expression of these genes. In addition,
we found that the expression of CD27, Anxa9, CCR9, and IL17Rβ were decreased in M-MDSCs from pristane-induce lupus mice, and INK128 could increase the expression of these genes. However, the expression of Anxa4 and TLR2 were increased in M-MDSCs, INK128 could inhibit Anxa4 and TLR2 expression in M-MDSCs in pristane-induce lupus mice. The differential expression of these surface molecules will help us to further differentiate more subtypes of MDSCs in SLE. And these results indicated that mTOR signal maybe a key pathway to regulate MDSCs in SLE development.
AMPK/mTOR signal pathway regulated TLR7/IFN-α-induced M-MDSCs differentiation in vitro

To further explore the effect of the AMPK/mTOR signal on M-MDSC expansion, BM cells were cultured in a medium supplemented with 40 ng/ml IL-6 and 40 ng/ml GM-CSF for 4 days. When the mTOR inhibitor INK128 was added to the culture, the percentage of M-MDSCs decreased (Fig. 4A–E) in a time- and dose-dependent manner. When the AMPK agonist metformin was added to the culture, M-MDSCs also decreased (Fig. 4F–I). The changes of G-MDSCs affected by metformin are shown in (Fig. S6D–I). Our previous study found that the TLR7/IFN-α signal could activate mTOR in MDSCs. To investigate the role of the AMPK/mTOR signal pathway in the TLR7/IFN-α-induced differentiation of M-MDSCs, four groups were set: control group, R848 treatment group, R848, and metformin treatment group. When the AMPK/mTOR signal pathway was regulated by the TLR7/IFN-α-induced differentiation of M-MDSCs in vitro, while metformin could inhibit these effects (Fig. 4J–K). The changes of G-MDSCs are shown in (Fig. S6E) and we found that IFN-α/TLR7 signal decreases the differentiation of G-MDSCs in vitro, while metformin could inhibit these effects. These results further indicated that the AMPK/mTOR signal pathway regulated the TLR7/IFN-α-induced differentiation of M-MDSCs in vitro.

Transcription factor IRF-8 was crucial for the differentiation of M-MDSCs

To explore the molecular mechanisms of the differentiation of M-MDSCs, the RNA sequencing results showed that the expression of IRF-8 in M-MDSCs from mice with lupus was higher than that in control mice (Fig. 5A). Meanwhile, the expression of IRF-8 in G-MDSCs from mice with lupus was lower than that in control mice (Fig. 5A, B). These results indicated that IRF-8 might play a crucial role in the differentiation of MDSC subtypes. To further explore the regulatory relationship between IRF-8 and AMPK/mTOR signal-related molecules, a co-expression analysis between IRF-8 and AMPK/mTOR signal-related molecules was conducted. IRF-8 was found to have a greater correlation with AMPK/mTOR signal-related molecules in M-MDSCs (Fig. 5B). The co-expression relationship of IRF-8 identified the significant roles in regulating MDSCs.

Next, to investigate whether IRF-8 was essential for the differentiation of MDSC subtypes, M-MDSCs and G-MDSCs were separately purified from spleens in mice with lupus and control mice using a MDCS isolation kit. Then, the expression of molecules related to myeloid cell differentiation in M-MDSCs and G-MDSCs in lupus development was compared. The expression of IRF-8 in M-MDSCs was found to be higher than that in G-MDSCs in both lupus BM- and G-MDSCs (Fig. 5C) and spleen-derived MDSCs (Fig. 5D). Other myeloid cell differentiation molecules (CCAAT/enhancer-binding protein α (CEBP-α), CCAAT/enhancer-binding protein β (CEBP-β), Retino blastomal 1 (Rb-1), and PU-1) were not changed. To identify the relationship between IRF-8 and AMPK/mTOR signal, BM cells were treated with R848, IFN-α, mTOR inhibitor INK128, and AMPK agonist metformin. R848 and IFN-α could elevate the expression of IRF-8 (Fig. 5E and F). However, the AMPK agonist metformin (Fig. 5H and I) and the mTOR inhibitor INK128 (Fig. 5G) could reduce the expression of IRF-8. We also detected the expression of p-AMPK (Fig. S8A, D), p-mTOR (Fig. S8B, D) and IRF-8 (Fig. S8C, D) in kidney in pristane-induced lupus mice and four mTOR signal molecules were highly expressed in the kidney tissues of SLE mice, and INK128 and metformin could significantly inhibit the expression of IRF-8 and the phosphorylation of mTOR. In addition, p-AMPK was low expressed in kidney tissues of SLE mice, and INK128 and metformin significantly promoted the phosphorylation of AMPK (Fig. S8A–D). Moreover, IFN-α/TLR7 signal promotes the expression of IRF-8 in vitro, while the AMPK agonist metformin (Fig. 5K and L) and the mTOR inhibitor INK128 (Fig. 5J) could inhibit these effects. Furthermore, to identify whether IRF-8 was essential for the differentiation of M-MDSCs, BM cells were cultured in a medium supplemented with 40 ng/ml IL-6 and 40 ng/ml GM-CSF for 4 days. At the same time, R848, IFN-α, and siIRF-8 were added to the culture. IFN-α/TLR7 to promote the differentiation of M-MDSCs in vitro, while siIRF-8 could inhibit these effects (Fig. S7M, N). The effect of IFR-8 on the differentiation of M-MDSCs is shown in (Fig. S7C).

Taken together, these results indicated that the IRF-8 signal was crucial for TLR7/IFN-α-induced differentiation of M-MDSCs.

miR-451a targeted IRF-8 in the differentiation of M-MDSCs

miRNAs are small noncoding RNAs that regulate gene expression by targeting miRNAs in a sequence-specific manner by controlling degradation or inhibiting translation. The expression of specific miRNAs is involved in immune cells differentiation and function. In order to explore the role of miRNA in MDSCs (M-MDSCs and G-MDSCs) in SLE and the specific regulatory mechanism, we performed high throughput sequencing of miRNA. RNA-seq data on the differential expression of microRNAs in M-MDSCs from spleens of mice with lupus and control mice with lupus were shown in the heat map (Fig. 6A). We found that 12 microRNAs (miR-143-3p, miR-451a, miR-199a-3p, miR-199a-5p, miR-144-3p, miR-143-5p, miR-547-3p, miR-214-5p, miR-199b-3p, miR-144b-5p, and miR-218-5p) are decreased and 3 microRNAs (miR-3473c, miR-3473e and miR-3473b) are increased. To further verify the accuracy of this result, the expression of microRNAs (miR-143-3p, miR-451a, miR-199a-3p, miR-144-3p, miR-143-5p, miR-547-3p, and miR-199b-5p) on M-MDSCs by qPCR (Fig. 6B) and G-MDSCs (Fig. 6S) from control mice and mice with lupus was detected. Further, IFN-α/TLR7 signal inhibits the expression of miR-451a. However, INK128 and metformin could inhibit these effects (Fig. 6C). Among the top 15 highly differentially expressed microRNAs, miR-451a was predicted to bind to IRF-8 mRNA using the miRNA-targeted prediction software (miRtarBase website) (Fig. 6D). The reverse transcription-polymerase chain reaction (RT-PCR) analysis of BM cells showed that miR-451a could knock down the expression of IRF-8, efficiently (Fig. 6E). To determine whether miR-451a regulated the expression of IRF-8 through binding to the 3’-untranslated regions (3’UTR) of IRF-8 mRNA, the entire 3’UTR of IRF-8 mRNA containing the presumed miR-451a-binding sites was fused downstream of the firefly luciferase gene in a reporter plasmid. The resulting plasmid was transfected into 293T and BM cells along with miR-NC, miR-451a, anti-miR-451a, and anti-miR-NC RNA oligonucleotides. As expected, the luciferase reporter activity in cells transfected with miR-451a was reduced in 293T and BM cells compared with the cells transfected with the scrambled control (Fig. 6F, G). Then, a similar luciferase reporter assay was performed in both 293T and BM cells. The luciferase activity of the mutant reporter gene was not affected
by the expression of miR-451a, whereas the activity of the wild-type reporter gene was markedly reduced (Fig. 6H).

To identify whether miR-451a was essential for the differentiation of M-MDSCs, BM cells were cultured in a medium supplemented with 40 ng/mL IL-6 and 40 ng/mL GM-CSF for 4 days. At the same time, miR-NC, miR-451a, anti-miR-451a, and anti-miR-NC were added to the culture in a single or mixed manner. Anti-miR-451a was found to promote the differentiation
of M-MDSCs in vitro, while miR-451a could inhibit this differentiation (Fig. 6I, J). Taken together, these results indicated that the transcription factor IRF-8 was targeted by miR-451a in the differentiation of M-MDSCs.

**DISCUSSION**

The important roles of MDSCs have gained attention recently. However, different views exist on the role of MDSCs in SLE development [14–17]. The number of G-MDSCs elevated in male lupus-prone (NZB × NZW) F1 mice compared with age-matched female mice, directly suppressing B-cell activation and differentiation in vitro [14]. Laquinimod delayed LN manifestations by inducing the expansion of M-MDSCs and G-MDSCs in (NZB × NZW) F1 mice [15]. The infusion of MDSCs obtained from C57BL/6 mice resulted in an expansion of the regulatory B-cell population and an improvement in renal pathology in mice with roquin/san lupus [16].

In contrast, some studies explored the abnormal expansion of MDSCs in the pathogenesis of SLE. The number of M-MDSCs increased in the blood and skin samples of patients with cutaneous lupus compared with healthy controls, and the number of T cells reduced in a dose-dependent manner [17]. Some studies
on the role of MDSCs in SLE development found that the percentages of MDSCs increased in patients with SLE, MRL/lpr mice, IMQ-lupus-prone mice, and mice with pristane-induced lupus [18, 20]. The percentage of MDSCs increased prior to the abnormal changes in Th17, Treg, T, and B cells during pristane-induced lupus development. TLR7/IFN-α-modified MDSCs promoted the imbalance of Th17/Tregs and were inclined to differentiate into macrophages via the mTOR pathway [21]. In the present study, G-MDSCs from diseased mice with lupus impaired Treg differentiation, and M-MDSCs promoted Th17-cell polarization [20]. Another study showed that MDSCs induced podocyte injury in LN via the ROS pathway [22]. The present study further investigated the role of MDSC subtypes in disease and found that the percentage of M-MDSCs increased in SLE development, and the activation of TLR7 signal and IFN-α in the lupus microenvironment jointly promoted the differentiation of M-MDSCs.

A previous study showed that TLR7/IFN-α-mTOR signaling was significantly activated in total MDSCs in mice with early-aged lupus, suggesting that the abnormal differentiation of MDSCs might provide an important insight into the early diagnosis and treatment of SLE [21]. Moreover, this study provided evidence that INK128, a second-generation mTOR inhibitor, attenuated SLE by regulating total MDSCs [21]. Recently, metformin, an AMPK agonist, was reported to relieve lupus symptoms by regulating abnormal T and B cells [35, 36]. The present study explored the treatment mechanism of metformin and found that metformin attenuated lupus symptoms by regulating the differentiation of M-MDSCs, and the percentage of M-MDSCs decreased by inhibiting the AMPK/mTOR signal pathway in vitro and in mice with pristane-induced lupus. Metformin could attenuate LN by reducing the glomerular injury in kidneys and reduce the inflammatory cell infiltration in joints and lungs by decreasing the differentiation of M-MDSCs.

The present study explored the relevant mechanism of AMPK-mTOR signaling pathway abnormality of MDSCs in SLE. Of course, MDSCs may not be the only target of Metformin and INK128 for the eventual mitigation of SLE, but in the early stage of disease (before abnormalities occur in other cells), we believe that MDSCs may be important disease target cells for metformin and INK128. Through our previous study and the present study, it was found that TLR7/IFN-A mediated AMPK-mTOR signaling pathway has a more obvious regulatory effect on M-MDSCs than G-MDSCs in MDSCs subtypes. Therefore, in this study, the effect of this signaling pathway on M-MDSCs was discussed and studied. We believe that there may be other signaling pathways that play an important role in regulating the differentiation and function of G-MDSCs in SLE.

The present study found that the percentage of M-MDSCs increased in mice with pristane-induced lupus, and the TLR7 signal activation and the high IFN-α level could promote the differentiation of M-MDSCs in vitro. Next, the study showed that the AMPK agonist metformin and the mTOR inhibitors INK128 and rapamycin could reduce the percentage of M-MDSCs in mice with pristane-induced lupus and TLR7- and IFN-α-induced BM differentiation into MDSCs in vitro. To explore the mechanism, whole-genome transcriptome profiling was performed using RNA-seq, revealing that the expression of IRF-8 was higher in M-MDSCs in mice with pristane-induced lupus. This indicated that IRF-8 was crucial for TLR7- and IFN-α-induced BM differentiation into MDSCs in vitro. Also, IRF-8 was targeted by miR-451a in the differentiation of M-MDSCs. Furthermore, the study showed that metformin-modified M-MDSCs could relieve lupus symptoms in mice with pristane-induced lupus. This study helped understand the development of M-MDSCs and might provide an important reference for SLE therapy by targeting M-MDSCs.

**MATERIALS AND METHODS**

**Antibodies and reagents**

INK128, rapamycin, and metformin were purchased from Selleckchem Inc. Recombinant mouse IFN-α2, anti-CD11b-fluorescein isothiocyanate (FITC), anti-G-α1-alkaline phosphatase (APC), anti-Ly6G-phycocyanin (PE), and anti-Ly6C-APC were purchased from Biolegend Inc. TRizol reagent and SYBR green dye were purchased from Invitrogen Inc. Dulbecco’s modified Eagle’s medium (DMEM) and fetal bovine serum (FBS) were purchased from Gibco Inc. Collagenase type D and DNase I were purchased from Roche Inc. Pristane, N-methyl-2-pyrrolidone (NMP), and polyvinyl pyrrolidone (PVP) were purchased from Sigma Inc. Antibodies for α-tubulin (2144), p-56 (48585), S6 (21275), p-4EBP-1 (28554), 4EBP-1 (96444), p-mTOR (5536T), p-AMPK (25375), and IRF-8 (83413T) were purchased from Signal Technology Inc. MDSC isolation kit, recombinant mouse IL-6, and GM-CSF were purchased from Miltenyi Biotec Inc. R848, Cpg, poly-IC, and TNF-α were purchased from Enzo Life Science Inc. Mouse albumin enzyme linked immunosorbent assay (ELISA) quantitation set, mouse anti-IGG, and anti-dsDNA IgG kit were purchased from Bethyl Laboratories Inc.
Mice
Female BALB/c mice (6–8 weeks old) were obtained from Model Animal Research Center of Nanjing University (Nanjing, China) and housed in pathogen-free conditions in a 12-h light and dark cycle. All procedures involving mice were approved by the institutional license for animal care and use based on the Animal Care Committee at Nanjing University.

At 10 weeks of age, BALB/c mice (n = 6–8) received a single intraperitoneal (i.p.) injection of 0.5 mL of pristane or PBS. The mice received daily i.p. treatment with metformin, INK128, or rapamycin (1 mg/kg prepared in a 1-methyl-2-pyrrolidone (NMP)/polyvinylpyrrolidone k30 (PVP) solution as described or vehicle (NMP/PVP solution) in the fifth month and administered to the mice 2 months later [39]. Peritoneal cells, spleen, BM, kidney, and blood were harvested.

MDSC depletion, isolation, and adoptive transfer experiment
At 10 weeks of age, BALB/c mice received a single intraperitoneal injection of 0.5 mL of pristane or PBS. After mice were treated with pristane for 5 months, 5-month-old BALB/c mice with pristane-induced lupus were injected i.p. with anti-Gr-1 antibodies (RB6-8C5, 200 µg; Biolegend, CA, USA) once every 4 days for another 2 months. For adoptive transfer, 2 × 10^7 MDSCs were washed twice and resuspended in 200 µL of PBS and injected into mice via the tail vein weekly. To isolate MDSCs, tibias and femurs were removed from BALB/c mice, and BM cells were flushed. Then, BM cells were cultured in a medium supplemented with 40 ng/mL murine IL-6 and 40 ng/mL murine GM-CSF in the absence or presence of R848, IFN-α, INK128, rapamycin, or metformin for 4 days. BM-derived MDSCs and spleen-derived MDSCs were purified from pristane-induced lupus mice using a MDSC isolation kit. G-MDSCs and M-MDSCs were purified from BM-derived MDSCs using the same kit.

MDSC differentiation assay
BM cells were cultured in the presence of 40 ng/mL GM-CSF and IL-6 for 4 days. At the same time, R848 (0–100 ng/mL), IFN-α (0–1000 U), metformin (0–5 mM), INK128 (0–100 nM), and rapamycin (0–100 nM) were added to the culture medium. In some experiments, 100 ng/mL R848, 500 U IFN-α, 2 mM metformin, 50 nM rapamycin, and 50 nM INK128 were incubated with 40 ng/mL GM-CSF and IL-6 for 4 days. After the different incubation periods, the cell phenotypes were determined by flow cytometry analysis.

Cell culture, transfections, luciferase reporter assay, and siRNA interference assay
HEK293T cells were purchased from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). The cells were maintained at 37 °C in 5% CO2 in DMEM supplemented with 10% FBS (Invitrogen). Synthetic RNA, mir-451a mimic, mir-451a inhibitor (antisense-mir-451a), control mimics, and siRNA against IRF-8 were synthesized by GenePharma (Shanghai). The sequences used were as follows: mir-451a mimic, 5′-AAACCGUUACCAUUACUGAGUU-3′; mir-451a inhibitor, 5′-AACUCAGAUAAUGGUUACCGGUU-3′; IRF-8 siRNA, 5′-CCGCGCAAGCAGGAUUACAATT-3′. HEK293 T cells and BM were transfected with oligonucleotides or indicated constructs using Lipofectamine 3000 (Invitrogen) according to the manufacturer’s protocols. To test the direct binding of mir-451a to the target gene IRF-8, a luciferase reporter assay (Promega) was performed. An shRNA sequence targeting IRF-8 cDNA was designed and synthesized by GenePharma.

RNA sequencing
After the pristane-induced lupus mouse model was established, G-MDSCs and M-MDSCs were purified from spleen-derived MDSCs mice using the MDSC isolation kit. Then, whole-genome transcriptome profiling was performed by RNA sequencing (RNA-Seq).

The RNA-seq was performed with the help of Novel Bioinformatics Co., Ltd (Shanghai, China). Total RNA was extracted using TRizol reagent (Invitrogen), and the RNA quality was checked using Bioanalyzer 2200 (Agilent). The RNA was kept at −80 °C. The RNA with RNA integrity number (RIN) > 8.0 was right for cDNA library construction. Next, the cDNA libraries for single-end sequencing were prepared using an Ion Total RNA-Seq Kit v2.0 (Life Technologies). The cDNA libraries were then processed for the proton sequencing process according to the commercially available protocols, followed by the mapping of single-end reads. The clean reads were aligned to the mouse genome using the MapSplice program (v2.2.0). Moreover, the pathway analysis was performed, and the EBseq algorithm was applied to filter the differentially expressed genes. The significant analysis and FDR analysis were also performed. The RNA-seq data were analyzed using log2 fold change (log2FC > 1) and false discovery rate (FDR) (FDR > 0.05). Besides, gene co-expression networks were used to find the relationships among different mRNAs related to IRF-8.

Flow cytometry analysis
The mice were sacrificed by cervical dislocation, the peritoneal cavity was lavaged with 3 mL of cold, sterile PBS, and the intraperitoneal fluid was harvested. The peritoneal cells were collected by centrifugation at 300 g for 10 min. BM cells were isolated as described previously by flushing femurs and tibiae. Single-cell suspensions of kidneys were prepared with collagenase type D (1 mg/mL) and DNase I (0.1 mg/mL) in Hank’s Balanced Salt Solution (HBSS) at 37 °C for 30 min. Then, the red cells from the kidneys were lysed. For cell surface marker staining, peritoneal cells, BM cells, splenocytes, Peripheral blood mononuclear cells (PBMCs), and lung and kidneys cells were prepared as single-cell suspensions. The cell suspensions were filtered through 70-µm cell strainers, and the lymphocytes were collected by centrifugation at 300 × g for 5 min at 4 °C. After washing, the cells were immediately prepared for flow cytometry. For the detection of mouse MDSC subsets, the cells were pre-incubated with FITC-conjugated anti-mouse CD11b mAb and APC-conjugated anti-mouse Gr1 mAb. For the detection of mouse G-MDSC and M-MDSC subsets, the cells were pre-incubated with FITC-conjugated anti-mouse CD11b mAb and PE-conjugated anti-mouse Ly6G mAb APC-conjugated anti-mouse Ly6C mAb. Then, the cells were stained for 30 min at 4 °C in the dark. After washing with the buffer, the cells were analyzed by flow cytometry. First, the CD11b+ cells were gated, and then, Ly6G and Ly6C markers were used to distinguish between G-MDSCs and M-MDSCs: G-MDSCs (CD11b+Ly6ChighLy6G−); M-MDSCs (CD11b+Ly6CintLy6G+).

Histological analyses
The sections were cut from paraffin-embedded tissues, fixed in formalin, and stained with hematoxylin and eosin.

RNA extraction and quantitative real-time PCR
Total RNA was isolated using TRizol reagent according to the manufacturer’s protocols. The real-time PCR assay was performed using SYBR green dye on the StepOne sequence detection system (Applied Biosystems, MA, USA). The relative abundance of genes was calculated using the 2−ΔΔCT formula, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as internal control. The primers can be found in supplementary material 2.

Western blot analysis
The proteins were extracted using standard techniques [40]. The antibodies for IRF-8, p-36, S6, p-4EBP-1, 4EBP-1, and horseradish peroxidase-conjugated anti-rabbit IgG for Western blot analysis were procured from Cell Signaling Technology (MA, USA). The protein bands were visualized using enhanced chemiluminescence (ECL) plus Western blotting detection reagents (Millipore, MA, USA). In the present study, α-tubulin was used as an internal control.

Cytokine ELISA
Anti-CD3 and anti-δsDNA IgG were analyzed using mouse anti-IgG and anti-δsDNA IgG Kit, and the sera were applied at dilutions of 1:100,000 and 1:300,000 according to the manufacturer’s protocols. Total urinary protein content was determined using a mouse albumin ELISA quantitation set (Bethyl Laboratories Inc.), and the urine was applied at dilutions of 1:100 according to the manufacturer’s protocols. The absorbance was determined using an ELX-800 Universal Microplate Reader (Bio-Tek, MA, USA).

Statistical analysis
The results were expressed as mean ± standard error of mean (SEM) of three independent experiments, and each experiment included triplicate sets. The data were statistically evaluated using one-way ANOVA followed by Dunnett’s test between the control and multiple-dose groups. A P value <0.05 was indicated as a statistically significant difference.
1. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110–21.
2. Leffers HCB, Lange T, Collins C, Uff-Moller CJ, Jacobsen S. The study of interactions between genome and exposure in the development of systemic lupus erythematosus. Autoimmun Rev. 2019;18:382–92.
3. Koutroukeras T, Healy T. Systemic lupus erythematosus and lupus nephritis. Nat Rev Drug Discov. 2014;13:173–4.
4. Reeves WH, Lee PF, Weinstein JS, Satoh M, Lu L. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol. 2009;30:455–64.
5. Toubi E, Vadasz Z. Innate immune-responses and their role in driving autoimmunity. Autoimmun Rev. 2019;18:306–11.
6. Crowl JT, Gray EE, Pestal K, Volkman HE, Stetson DB. Intracellular nucleic acid detection in autoimmunity. Ann Rev Immunol. 2017;35:313–36.
7. Funes SC, Rios M, Escobar-Vera J, Kalgemis AM. Implications of macrophage polarization in autoimmunity. Immunology. 2018;154:186–95.
8. Chalmers SA, Chitu V, Ramanujan M, Putterman C. Therapeutic targeting of macrophages in lupus nephritis. Discov Med. 2015;20:43–9.

REFERENCES

1. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110–21.
2. Leffers HCB, Lange T, Collins C, Uff-Moller CJ, Jacobsen S. The study of interactions between genome and exposure in the development of systemic lupus erythematosus. Autoimmun Rev. 2019;18:382–92.
3. Koutroukeras T, Healy T. Systemic lupus erythematosus and lupus nephritis. Nat Rev Drug Discov. 2014;13:173–4.
4. Reeves WH, Lee PF, Weinstein JS, Satoh M, Lu L. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol. 2009;30:455–64.
5. Toubi E, Vadasz Z. Innate immune-responses and their role in driving autoimmunity. Autoimmun Rev. 2019;18:306–11.
6. Crowl JT, Gray EE, Pestal K, Volkman HE, Stetson DB. Intracellular nucleic acid detection in autoimmunity. Ann Rev Immunol. 2017;35:313–36.
7. Funes SC, Rios M, Escobar-Vera J, Kalgemis AM. Implications of macrophage polarization in autoimmunity. Immunology. 2018;154:186–95.
8. Chalmers SA, Chitu V, Ramanujan M, Putterman C. Therapeutic targeting of macrophages in lupus nephritis. Discov Med. 2015;20:43–9.

ACKNOWLEDGEMENTS

This work was supported by the National Natural Science Foundation of China (No. 32070883, 31872732), Jiangsu Province Six Talent Peaks Project (YY-021), Jiangsu Province key Social and Development R&A Grant (BE2019706).

AUTHOR CONTRIBUTIONS

SG designed experiments. SGP and LD performed experiments; DH, ZDY, XYJ, and XYJ wrote the manuscript.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41420-021-00568-z.

Correspondence and requests for materials should be addressed to H.D. or Y.H.

Reprints and permission information is available at http://www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
